-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with acute lymphoblastic leukemia (ALL) are at increased risk of thrombosis and/or bleeding events during early chemotherapy, particularly when
Therefore, a research team attempted to conduct a retrospective cohort study at the University of Chicago to examine D-dimers as biomarkers
Figure 1: Cumulative incidence
In patients with D-dimer (≥ 4 μg/mL), the 100-day cumulative incidence of venous or arterial thrombosis (95% CI [CI]) was 52.
Figure 2: ROC curve
When testing for potential confounders in a range of binary logistic regression models, the association between D-dimer and thrombosis persisted
In summary, D-dimer levels at the time of all diagnoses are associated with venous or arterial thrombosis over
Original Source:
Anderson DR, Stock W, Karrison TG, Leader A.